Skip to content
Clinical ResearchResearch compound

Enclomiphene (Androxal)

Unapproved testosterone-boosting compound: a cleaner version of Clomid, developed for low hormone levels in men.

Available at
DEUSPOWER logo
DEUSPOWERProduct page

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Enclomiphene (Androxal) vial

DETAILED OVERVIEW

What is Enclomiphene (Androxal)?

Enclomiphene (Androxal) is one of the two components of the medicine Clomid: it lacks the other one, which causes Clomid's mood side effects. It was developed for low testosterone in men but has never been approved as a medicine: the US authority asked for further data in 2016, and the developing company never resubmitted its application. After stopping steroids, it is also used to restart the body's own hormone production.

It blocks the estrogen signal in the pituitary gland, so the gland produces more of the hormones that stimulate the testicles. In studies this raised testosterone while sperm production was preserved, but its long-term safety has not been proven. Side effects can include vision problems, headache, mood swings and, rarely, breast growth, and with this type of hormone modulator the risk of blood clots also rises. It must not be used in pregnancy, and in competitive sport it is banned both in and out of competition.

Mechanism

Estrogen receptor blocker; without the mood-disturbing form of clomiphene

Half-life

~5 days (cleaner than Clomid mixed t1/2)

Onset

LH rise 24-72 h, Test recovery 2-4 weeks

Legal status

NOT FDA-approved (CRL 2016), US-compounding + EU research-pharm + UGL

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS, SERM)
AR bindingER-α competitive affinity moderate-to-high (~10 nM Ki).…
Active half-life~5 days
Detection windowWADA-accredited GC-MS/LC-MS/MS urine detection ~1-2 months (shorter than Clomid due to absence of zuclomiphene accumulation).
AromatizationDoes not aromatize – selectively blocks ER-α at the pituitary, NOT aromatase. Clinically E2 rises slightly (LH↑ → testicular E2↑), but cleaner profile than Clomid (no zuclomiphene-mediated intrinsic agonist).
HepatotoxicityLow – non-17α-alkylated, non-steroidal. Trial-database adverse-event-rate <1% ALT/AST elevation (Wiehle 2014 + Kim 2016 Phase III data). Hepatic tolerance excellent.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Visual disturbances: blurred vision, light flashes (photopsia), glare. A known SERM-class effect from retinal ER modulation – rarer and milder than with Clomid, but persistent symptoms warrant immediate discontinuation.
  • Elevated estradiol (E2): the increased LH raises testicular testosterone and, via aromatization, can raise E2, presenting as water retention, mood swings and rarely gynecomastia.
  • Headache: the most commonly reported adverse event in the Phase III trials, usually mild and transient.
  • Mood swings, irritability: markedly rarer and milder than with Clomid (the zuclomiphene isomer is absent), but not fully eliminated – emotional lability and irritability can occur.
  • Nausea and gastrointestinal discomfort: GI upset can occur and is reduced by taking the dose with a morning meal.
  • Venous thromboembolism risk: estrogen-receptor modulation carries a prothrombotic effect across the SERM class; deep vein thrombosis and pulmonary embolism risk exists, especially with predisposing factors.
  • Unknown long-term safety profile: the FDA Complete Response Letter (2016) was issued precisely over missing long-term cardiovascular, bone and prostate data; chronic use (>3 months) safety is unproven.

Contraindications · 6

  • Pregnancy and teratogenicity: clomiphene compounds are contraindicated in pregnancy (Pregnancy Category X); heightened caution is needed if a female partner could conceive. Risk of fetal harm in women.
  • Prior or active thromboembolism: avoid in deep vein thrombosis, pulmonary embolism, stroke history or known thrombophilia due to the prothrombotic effect of SERMs.
  • Active or severe liver disease: a relative contraindication in active hepatic dysfunction due to hepatic metabolism; liver function monitoring required.
  • Hormone-sensitive tumor: avoid in estrogen- or androgen-dependent tumors (e.g. prostate cancer) or undiagnosed abnormal genital bleeding.
  • Primary (hypergonadotropic) hypogonadism: efficacy depends on an intact HPTA and functioning testes; it is ineffective and not indicated in primary testicular failure (high LH/FSH).
  • Competitive athletes: listed on the WADA S4 prohibited list (hormone and metabolic modulators, SERMs), banned in and out of competition for men.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Enclomiphene (Androxal)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.